Kiniksa Pharmaceuticals Ltd (KNSA) — Cash Flow Quality Index
Kiniksa Pharmaceuticals Ltd (KNSA) has a Cash Flow Quality Index of 2.22x as of March 2026. Operating cash flow of $50.20 Million exceeds net income of $22.59 Million, indicating high earnings quality where cash backs reported profits. Also explore KNSA current and non-current assets for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Kiniksa Pharmaceuticals Ltd Cash Flow Quality Index (2022–2023)
Historical Cash Flow Quality Index for Kiniksa Pharmaceuticals Ltd across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how tangible is Kiniksa Pharmaceuticals Ltd's equity to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Kiniksa Pharmaceuticals Ltd (2022–2023)
Year-by-year earnings quality comparison for Kiniksa Pharmaceuticals Ltd. For live market cap and the full company financial profile, see Kiniksa Pharmaceuticals Ltd (KNSA) total market value.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 0.94x | $13.30 Million | $14.08 Million | ▲ +2882.1% |
| 2022 | 0.03x | $5.81 Million | $183.36 Million | — |